Kelly Norsworthy

Adjunct Assistant Professor

Johns Hopkins Hospital

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kelly Norsworthy is an Adjunct Assistant Professor at Johns Hopkins Hospital in the United States. Her research focuses on drug development and treatment strategies for conditions such as acute myeloid leukemia and myelodysplastic syndromes. She has contributed to several FDA approval summaries and has published on critical topics surrounding disease response and patient survival outcomes.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Daniel A. Pollyea

UNITED STATES

View details

Ashkan Emadi

University of Maryland School of Medicine

UNITED STATES

View details

Bryan Hambley

University of Cincinnati

UNITED STATES

View details

Sarah Kashanian

University of Texas Southwestern Medical Center

UNITED STATES

View details

Amer M. Zeidan

Yale University School of Medicine

UNITED STATES

View details

Firas El Chaer

University of Virginia Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kelly Norsworthy

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Considerations for Drug Development in Myelodysplastic Syndromes

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid Leukemia

<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification

Increased body mass index is a risk factor for acute promyelocytic leukemia.

Meaningful response criteria for myelodysplastic syndromes.

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.

Collaborators (6)

Daniel A. Pollyea

Ashkan Emadi

Bryan Hambley

Sarah Kashanian

Amer M. Zeidan

Firas El Chaer

Make your next move.